NITRO clinical trial information

Dataset Name: A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer
Author: Prof Andrew Davidson, Royal Perth Hospital
Thoracic Oncology Group Australasia
Funding: Cancer Council WA, Cancer Council QLD, Cancer Council NSW, National Health and Medical Research Council.
DOI: 10.58106/914n-jz74
Date made available: 2023

Subject: Chemotherapy
Individual participant data
Patient sample size: 372

Dataset description: Patients starting one of five, prespecified, platinum-based doublets as first-line chemotherapy for advanced NSCLC were randomly allocated treatment with or without nitroglycerin 25 mg patches for 2 days before, the day of, and 2 days after, each chemotherapy infusion. Progression-free survival (PFS) was the primary end point. Accrual was stopped after the first interim analysis of 270 events. Chemotherapy was predominantly with carboplatin and gemcitabine (79%) or carboplatin and paclitaxel (18%). The final analysis included 345 events in 372 participants with a median follow-up of 33 months.

Requests for Data: Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to

Link to main trial page

Link to publication